Ophthalmic solution comprising diquafosol

Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of producti...

Full description

Saved in:
Bibliographic Details
Main Authors Hosoi Kazuhiro, Sonoda Masaki, Nakamura Masatsugu, Fukui Yoko, Saito Mikiko, Ikei Tatsuo, Sakatani Akiko, Kuwano Mitsuaki, Inagaki Koji
Format Patent
LanguageEnglish
Published 08.11.2016
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
Bibliography:Application Number: US201314386169